Evotec SE ADR (EVO) is a renowned global drug discovery and development corporation based in Germany. Since its establishment in 1993, it has been committed to the discovery and development of new pharmaceuticals through partnerships with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.
A key distinctive factor about Evotec SE is its focus on unmet medical needs and integrated early-stage research. The company aims to facilitate the production of breakthrough therapies and employs cutting-edge technologies within high throughput screening, protein crystallography, and drug metabolism and pharmacokinetics to achieve its goals.
Over the years, Evotec SE has strategically expanded its activities to include the fields of neurology, inflammation, metabolic disorders, and oncology. This has allowed the firm to diversify and become a strong player in the pharmaceutical industry. Some of Evotec's successful collaborations include partnerships with major pharmaceutical giants like Bayer, Boehringer Ingelheim, Celgene, and Genentech.
As evidenced by its stellar reputation and broad global reach, Evotec SE believes firmly in partnership and collaboration for innovative drug discovery. Its business model focuses on establishing early-stage alliances with partners, and it provides various types of drug discovery services, which include target identification, hit identification, hit-to-lead services, and lead optimization, as well as clinical testing.
Moreover, Evotec SE's commitment to progressive strategies and pursuit of innovation doesn't stop at drug discovery; the firm has also been instrumental in pioneering translational research. This consists of transforming scientific findings from laboratory studies into clinical applications to diagnose, treat, and prevent diseases.
Evotec's shares are listed on the Frankfurt Stock Exchange under the ticker symbol EVT and in the USA as American Depository Receipts (ADRs) under the symbol EVTCY.
Despite challenging market conditions and increasing pharmaceutical industry complexity, Evotec's strong balance sheet, innovative drive, and collaborative business model make it well-positioned to play a pivotal role in drug discovery and development. Their consistent focus on science and patient needs enables them to contribute significantly to the fight against a myriad of diseases.
In the future, Evotec SE looks set to continue this approach, striving to develop not only treatments but also potential cures for some of the most challenging diseases, fully encapsulating the company’s mantra of acting today for a healthier tomorrow.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Evotec SE has begun its first human clinical trial for JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses. This advancement is supported by two Accelerated Antibodies Program contracts totaling up to $123.9 million, emphasizing the use of continuous manufacturing for biodefense readiness. The clinical study is registered on ClinicalTrials.gov with identifier NCT07595458, showcasing Evotec's commitment to scalable development and continuous manufacturing in biodefense.
Just - Evotec Biologics, a subsidiary of Evotec SE, has initiated a Phase 1 clinical trial for JST-018, an investigational antibody cocktail targeting orthopoxviruses. This program, developed under the U.S. Department of War's Accelerated Antibodies Program, aims to provide a prophylactic therapy for warfighters against biological threats like smallpox and mpox. The manufacturing of clinical trial materials was completed at the company's J.POD® Redmond facility, showcasing its continuous bioprocessing platform for rapid and cost-effective medical countermeasures.
Evotec and Plectonic Biotech have announced a research collaboration to develop a novel immunotherapy approach for solid tumors. The partnership will combine Plectonic's LOGIBODY® technology, which uses logic-gated DNA-protein therapeutics for highly specific tumor recognition, with Evotec's BiTco platform, designed to enhance T-cell activation and persistence. This collaboration aims to overcome current limitations of T-cell engager therapies in solid tumors by improving precision and potency through integrated technologies.
Evotec (NASDAQ:EVO) shares gapped down following weaker-than-expected quarterly earnings, missing analyst estimates for both EPS and revenue. The company reported a loss of $0.14 per share against an expected $0.05 loss, and revenue of $161.2 million compared to estimates of $173.87 million. This performance led to analyst downgrades and a consensus "Hold" rating, with the stock remaining unprofitable and holding a negative net margin.
Evotec SE (EVO), a German drug manufacturing company, presents a compelling investment opportunity despite current unprofitability and revenue decline. Analysts project an 84.27% potential upside, driven by strategic collaborations with major institutions and ongoing innovation in drug discovery. The stock is technically oversold, suggesting a buying opportunity for risk-tolerant investors focused on long-term growth.